上海医药集团股份有限公司 关于阿立哌唑片获得菲律宾药品注册证书的公告

Drug Overview - Shanghai Pharmaceuticals has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole Tablets, allowing the product to be marketed in the Philippines [1] - Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and can also be used as an adjunct treatment for depression [1] - The drug was first approved by the FDA in the United States in November 2002 and was approved for domestic sale in China in October 2004 [1] Market Competition - In the Philippines, Aripiprazole Tablets face competition from five other companies, including OTSUKA PHARM, ZYDUS PHILS. INC., and MULTICARE PHARM [2] - The total sales revenue for Aripiprazole Tablets (10 mg) in the Philippines is projected to be $2.39 million in 2024 according to IQVIA data [3] Impact on Company - The approval of Aripiprazole Tablets in the Philippines is expected to positively impact the company's efforts to expand into overseas markets and accumulate valuable experience [4]